---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-014289"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:37:08.314186+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dermata nears completion of DMT310 Phase 3 enrollment; Q3 2024 cash at $6.1M

## Summary
- Enrollment in DMT310 Phase 3 STAR-1 acne trial expected to complete by end of 2024; topline results Q1 2025.
- Cash and equivalents of $6.1M at Sep 30, 2024; expected to fund operations into Q2 2025.
- Raised $7.8M in gross proceeds during 2024, including $5.1M in Q3 2024.
- R&D expenses $2.4M in Q3 2024, up from $0.9M due to STAR-1 clinical trial costs.
- G&A expenses $0.8M in Q3 2024, down from $0.9M in Q3 2023 on lower insurance costs.

## SEC filing metadata
- accession: 0001654954-24-014289
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/0001654954-24-014289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-014289
- JSON: https://secwatch.observer/filing/0001654954-24-014289.json
- Plain text: https://secwatch.observer/filing/0001654954-24-014289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.